These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 2289199)
1. Selective restoration of immunosuppressive effect of cytotoxic agents by thymopoietin fragments. Dénes L; Szende B; Hajós G; Szporny L; Lapis K Cancer Immunol Immunother; 1990; 32(1):51-4. PubMed ID: 2289199 [TBL] [Abstract][Full Text] [Related]
2. Effect of splenopentin (SP-5) on the antibody formation in immunosuppressed mice. Diezel W; Eckert R; Forner K; Sönnichsen N Exp Clin Endocrinol; 1986 Jul; 87(2):215-8. PubMed ID: 3489630 [TBL] [Abstract][Full Text] [Related]
3. Splenopentin--influence on antibody formation in immunosuppressed animals and on phagocytic capability of human granulocytes. Diezel W; Eckert R; Müller GM; Forner K; Sönnichsen N Arch Geschwulstforsch; 1989; 59(3):161-4. PubMed ID: 2667491 [TBL] [Abstract][Full Text] [Related]
4. Selective effects of immunosuppressive agents against the delayed hypersensitivity response and humoral response to sheep red blood cells in mice. Doherty NS Agents Actions; 1981 May; 11(3):237-42. PubMed ID: 7257950 [TBL] [Abstract][Full Text] [Related]
5. Therapeutic possibilities of thymopoietin fragments (TP3 and TP4) based on experimental animal models. Dénes L; Szende B; Hajós G; Szporny L; Lapis K Drugs Exp Clin Res; 1987; 13(5):279-87. PubMed ID: 3500029 [TBL] [Abstract][Full Text] [Related]
6. Stimulation by thymopoietin oligopeptides of lectin-dependent cell-mediated cytotoxicity in patients with systemic lupus erythematosus. Perl A; Gonzalez-Cabello R; Nékám K; Gergely P; Fehér J J Clin Lab Immunol; 1985 Nov; 18(3):119-22. PubMed ID: 3910838 [TBL] [Abstract][Full Text] [Related]
7. Effects of thymopoietin pentapeptide (TP-5) on in vitro and in vivo IgE production by atopic dermatitis cell subsets. Cooper KD; Kang K; Hanifin JM Diagn Immunol; 1983; 1(3):211-5. PubMed ID: 6388971 [TBL] [Abstract][Full Text] [Related]
8. Regulatory influence of thymopentin on splenic T cell sets of thymectomized and aged mice. Newcomb EW; Goldberg EH; de Sousa M; Goldstein G; Boyse EA; Scheid MP Transplantation; 1985 Nov; 40(5):520-7. PubMed ID: 3904090 [TBL] [Abstract][Full Text] [Related]
9. The course of LCMV infection in euthymic and athymic mice pretreated with immunomodulatory agents. Anderlik P; Szeri I; Bános Z; Barna Z Acta Microbiol Hung; 1992; 39(3-4):235-9. PubMed ID: 1343936 [TBL] [Abstract][Full Text] [Related]
11. Immunosuppressive effects of barbituric acid derivatives. I. Influence on humoral antibody response and phagocytic activity in mice. Güttner J; Zschiesche W; Werner W Chemotherapy; 1973; 19(1):47-52. PubMed ID: 4747575 [No Abstract] [Full Text] [Related]
12. RM-11, an isoxazole derivative, accelerates restoration of the immune function in mice treated with cyclophosphamide. Zimecki M; Artym J; Ryng S; Obmińska-Mrukowicz B Pharmacol Rep; 2008; 60(2):183-9. PubMed ID: 18443379 [TBL] [Abstract][Full Text] [Related]
13. The effect of various immunosuppressive agents on mouse peritoneal macrophages and on the in vitro phagocytosis of Escherichia coli O4:K3:H5 and degradation of 125I-labelled HSA-antibody complexes by these cells. Gadeberg OV; Rhodes JM; Larsen SO Immunology; 1975 Jan; 28(1):59-70. PubMed ID: 1090520 [TBL] [Abstract][Full Text] [Related]
14. The effect of thymopoietin 32-34 (TP3) on suramin-induced inhibition on delayed type hypersensitivity in guinea pigs. Dénes L; Hajós G; Szporny L; Szende B; Lapis K; Sipka S; Szegedi G Immunol Invest; 1987 Jun; 16(4):275-9. PubMed ID: 3323037 [TBL] [Abstract][Full Text] [Related]
15. Syntheses and effects of [Glu34]-thymopoietin II fragment 32-45 and its analogs on the impaired T-cell transformation in a patient with common variable immunodeficiency. Abiko T; Shishido H; Sekino H Biotechnol Appl Biochem; 1986; 8(2-3):160-71. PubMed ID: 3488750 [TBL] [Abstract][Full Text] [Related]
16. The effect of TP-5 and its analogs on skin grafts in mice. Szende B; Kisfaludy L; Lapis K; Dénes L; Szporny L; Nyéke O; Schön I; Hajós G; Ember J; Constantin M J Immunopharmacol; 1985; 7(1):67-78. PubMed ID: 3891868 [TBL] [Abstract][Full Text] [Related]
17. Immunostimulation by TP-5 in immunocompromised patients and animals--current status of investigation. Waymack JP; Alexander JW Comp Immunol Microbiol Infect Dis; 1986; 9(2-3):225-32. PubMed ID: 3539496 [TBL] [Abstract][Full Text] [Related]
18. Antibody plaque reduction in vitro and in vivo: a rapid assay for immunosuppressive agents. Gavin J; Waterbury W; Freidman H Transplant Proc; 1969 Mar; 1(1):413-5. PubMed ID: 4944252 [No Abstract] [Full Text] [Related]
20. The effect of TP-5 on the production of C3, PGE2, and TXB2 by macrophages obtained from burned guinea pigs. Ogle CK; Ogle JD; Keynton L; Nagy H; Alexander JW J Burn Care Rehabil; 1989; 10(2):146-50. PubMed ID: 2651450 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]